Call Boomerang Books 1300 36 33 32

Get Latest Book News + FREE Shipping. Subscribe to the Boomerang Books Bulletin eNewsletter right now!

Description - Formulation and Analytical Development for Low-dose Oral Drug Products by Jack Zheng

There are unique challenges in the formulation, manufacture, analytical chemistry, and regulatory requirements of low-dose drugs. This book provides an overview of this specialized field and combines formulation, analytical, and regulatory aspects of low-dose development into a single reference book. It describes analytical methodologies like dissolution testing, solid state NMR, Raman microscopy, and LC-MS and presents manufacturing techniques such as granulation, compaction, and compression. Complete with case studies and a discussion of regulatory requirements, this is a core reference for pharmaceutical scientists, regulators, and graduate students.

Buy Formulation and Analytical Development for Low-dose Oral Drug Products by Jack Zheng from Australia's Online Independent Bookstore, Boomerang Books.

Book Details

ISBN: 9780470056097
ISBN-10: 0470056096
Format: Hardback
(241mm x 156mm x 28mm)
Pages: 462
Imprint: Wiley-Blackwell
Publisher: John Wiley and Sons Ltd
Publish Date: 10-Mar-2009
Country of Publication: United States

Book Reviews - Formulation and Analytical Development for Low-dose Oral Drug Products by Jack Zheng

» Have you read this book? We'd like to know what you think about it - write a review about Formulation and Analytical Development for Low-dose Oral Drug Products book by Jack Zheng and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a Boomerang Books Account Holder - it's free to sign up and there are great benefits!)

Write Review


Author Biography - Jack Zheng

Jack Zheng, PhD, is Research Advisor and Team Leader in the Pharmaceutical Sciences R&D Division of Eli Lilly and Company and Adjunct Professor at Beijing University. Dr. Zheng is the author of more than thirty articles and several book chapters. He has been invited to present his work at numerous national and international scientific meetings. He was involved in more than ten new drug product development and regulatory filing with the Food and Drug Administration.